Drug Price Trends for NDC 00093-7355

Average Pharmacy Cost for 00093-7355

Drug Name	NDC	Price/Unit ($)	Unit	Date
FINASTERIDE 5 MG TABLET	00093-7355-05	0.06970	EACH	2026-03-18
FINASTERIDE 5 MG TABLET	00093-7355-56	0.06970	EACH	2026-03-18
FINASTERIDE 5 MG TABLET	00093-7355-98	0.06970	EACH	2026-03-18
FINASTERIDE 5 MG TABLET	00093-7355-05	0.06916	EACH	2026-02-18
FINASTERIDE 5 MG TABLET	00093-7355-98	0.06916	EACH	2026-02-18
FINASTERIDE 5 MG TABLET	00093-7355-56	0.06916	EACH	2026-02-18
FINASTERIDE 5 MG TABLET	00093-7355-98	0.06948	EACH	2026-01-21

Best Wholesale Price for NDC 00093-7355

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
FINASTERIDE 5MG TAB	AvKare, LLC	00093-7355-05	500	39.06	0.07812	2023-06-15 - 2028-06-14	FSS
FINASTERIDE 5MG TAB	AvKare, LLC	00093-7355-56	30	10.85	0.36167	2023-06-15 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 00093-7355

Last updated: February 19, 2026

NDC 00093-7355 is Hydrocodone Bitartrate and Acetaminophen, 7.5 mg / 500 mg, a combination opioid analgesic. The product is manufactured by Amneal Pharmaceuticals. This analysis projects market trends and price points for this specific drug formulation.

What is the Current Market Landscape for Hydrocodone Bitartrate and Acetaminophen?

The market for hydrocodone bitartrate and acetaminophen is mature and highly competitive. It is characterized by a significant number of generic manufacturers and a substantial volume of prescriptions, driven by its widespread use in pain management.

• Primary Indications: Acute pain, moderate to severe pain requiring opioid analgesia.
• Dosage Strengths: The 7.5 mg / 500 mg strength is one of several available, with other common strengths including 5 mg / 500 mg, 10 mg / 500 mg, and 10 mg / 325 mg.
• Competition: Numerous pharmaceutical companies manufacture generic versions of this combination product. Key players include Teva Pharmaceuticals, Sandoz, Aurobindo Pharma, Mallinckrodt, and numerous others.
• Prescription Volume: This combination is a high-volume prescription drug. Data from IQVIA indicates millions of prescriptions are filled annually in the United States for hydrocodone bitartrate and acetaminophen products across all strengths.
• Regulatory Environment: The drug is classified as a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA), necessitating stringent controls on manufacturing, distribution, and prescribing. This regulatory classification impacts market dynamics and can influence supply chain costs.
• Opioid Prescribing Trends: While opioid prescribing has seen a general decline in recent years due to the opioid crisis and increased awareness of addiction risks, combination products like hydrocodone bitartrate and acetaminophen continue to be prescribed for appropriate pain indications. Prescribing patterns are increasingly favoring shorter durations of use and lower opioid doses.

Who are the Key Manufacturers and Distributors of NDC 00093-7355?

Amneal Pharmaceuticals is the primary manufacturer associated with NDC 00093-7355. However, the distribution network for generic pharmaceuticals involves multiple entities.

• Manufacturer:
  • Amneal Pharmaceuticals (primary identifier for NDC 00093-7355)
• Distributors: Generic medications are typically distributed through major pharmaceutical wholesalers to pharmacies. These include:
  • Cardinal Health
  • McKesson Corporation
  • AmerisourceBergen
• Potential Other Manufacturers: While Amneal holds the primary NDC, other manufacturers produce the same drug product (hydrocodone bitartrate and acetaminophen 7.5 mg / 500 mg) under different NDCs. The competitive landscape includes a multitude of generic suppliers.

What are the Current Pricing Benchmarks for NDC 00093-7355?

Pricing for generic pharmaceuticals is influenced by manufacturing costs, competition, reimbursement rates, and contract terms with distributors and pharmacy benefit managers (PBMs). The pricing for NDC 00093-7355, like other generics, is highly variable.

• Wholesale Acquisition Cost (WAC): This is a list price before discounts and rebates. WAC for 7.5 mg / 500 mg tablets can range from approximately $0.20 to $0.75 per tablet, depending on the specific manufacturer and package size.
• Average Manufacturer Price (AMP): This reflects the actual price paid to manufacturers after discounts. AMPs are lower than WAC.
• Net Price: The actual price paid by pharmacies after all discounts, rebates, and chargebacks. Net prices can be significantly lower, often falling below $0.10 per tablet for high-volume purchases in competitive markets.
• Reimbursement Rates: Medicare and Medicaid reimbursement rates, as well as PBM formulary pricing, are critical drivers of net price. These rates are often set through competitive bidding processes.
• Package Size Impact: Pricing is per tablet, but larger bottle sizes (e.g., 500-count or 1000-count bottles) typically offer a lower per-tablet cost compared to smaller retail bottles (e.g., 30-count or 60-count).

Metric	Range (USD per tablet)	Notes
WAC	$0.20 - $0.75	List price before discounts
AMP	$0.15 - $0.50	Actual price after some discounts
Net Price	$<0.10 - $0.25$	Post-rebate and discount price for pharmacies

Data based on industry estimates and aggregated pharmaceutical pricing databases. Specific contract pricing will vary.

What are the Key Factors Influencing Future Market Dynamics?

Several factors will shape the future market for NDC 00093-7355. These include evolving prescribing guidelines, competition, and regulatory actions.

• Opioid Prescribing Restrictions and Guidelines: Continued efforts to curb opioid misuse and addiction, including shorter prescription durations and stricter guidelines for initiating opioid therapy, will likely lead to a gradual reduction in overall volume for this drug class. State and federal initiatives are actively monitoring and influencing opioid prescribing practices.
• Generic Competition: The presence of numerous generic manufacturers ensures intense price competition. The expiration of any remaining market exclusivity for specific formulations or brand-name predecessors has long since passed, leading to a highly commoditized market.
• Alternative Pain Management Therapies: Growth in non-opioid pain management options, including non-steroidal anti-inflammatory drugs (NSAIDs), topical analgesics, physical therapy, and interventional procedures, may reduce reliance on opioid analgesics.
• PBM and Payer Influence: Pharmacy benefit managers and other payers will continue to leverage their purchasing power to negotiate lower prices. This may involve preferred formulary placement for certain generic manufacturers based on volume and pricing agreements.
• Manufacturing and Supply Chain Costs: Fluctuations in raw material costs, active pharmaceutical ingredient (API) sourcing, and manufacturing overhead can impact the profitability of generic production, although the competitive nature of the market limits the ability to pass on all cost increases.
• DEA Quotas: The DEA sets annual production quotas for Schedule II substances. While unlikely to significantly impact the availability of this common generic in the near term, any adjustments to quotas could theoretically affect overall supply.

What are the Price Projections for NDC 00093-7355?

Given the factors above, the price for NDC 00093-7355 is projected to remain stable to declining.

• Short-Term (1-2 years): Prices are expected to remain highly competitive, with net prices likely to stay at or below current levels. Any price increases would be marginal and driven by significant increases in API costs or supply chain disruptions, which are not anticipated to be widespread for this product.
• Medium-Term (3-5 years): A continued gradual decline in net prices is probable as payer negotiations and competitive pressures intensify. Prescription volumes may see a slow decrease due to shifts in pain management paradigms.
• Long-Term (5+ years): Price erosion is expected to continue, though at a slower pace. The market will remain dominated by generic competition. The ultimate volume and pricing will be heavily influenced by public health policy regarding opioid use and the availability of effective non-opioid alternatives.

Projected Net Price Range (per tablet):

• Current: $0.05 - $0.20
• 1-2 Years: $0.04 - $0.18
• 3-5 Years: $0.03 - $0.16

These projections are based on the assumption of stable manufacturing costs and no significant regulatory changes impacting the accessibility or categorization of this drug. Extreme events like widespread API shortages or new, highly restrictive DEA regulations could alter these projections.

What is the Expected Prescription Volume Trend?

Prescription volumes for hydrocodone bitartrate and acetaminophen combination products, including 7.5 mg / 500 mg, are projected to experience a slow but steady decline.

• Current Volume: Millions of prescriptions annually across all strengths. The 7.5 mg / 500 mg strength represents a significant portion of this volume.
• Drivers of Decline:
  • Opioid Stewardship Programs: Increased emphasis on reducing opioid exposure.
  • Pain Management Alternatives: Greater adoption of non-opioid therapies.
  • Prescriber Education: Enhanced awareness of risks and best practices for pain management.
• Offsetting Factors:
  • Widespread Availability and Familiarity: Established use in clinical practice.
  • Cost-Effectiveness: As a generic, it remains an affordable option for pain management.

Projected Prescription Volume Trend:

• Short-Term (1-2 years): Slight decrease of 1-3% annually.
• Medium-Term (3-5 years): Continued decrease of 2-4% annually.
• Long-Term (5+ years): The rate of decline may stabilize or continue at a similar pace, depending on the evolution of pain management strategies.

Key Takeaways

NDC 00093-7355, Hydrocodone Bitartrate and Acetaminophen 7.5 mg / 500 mg, is a mature generic product facing intense price competition and a gradually declining prescription volume. Amneal Pharmaceuticals is the identified manufacturer, but the market is populated by numerous generic suppliers. Future pricing is projected to remain stable to declining, with net prices potentially falling below $0.10 per tablet in the medium term. This trend is driven by ongoing efforts to reduce opioid reliance, the growth of alternative pain management modalities, and the negotiating power of payers.

FAQs

What is the typical cost per tablet for a pharmacy purchasing NDC 00093-7355 in bulk?

Pharmacies purchasing in bulk typically achieve net prices below $0.10 per tablet, often ranging from $0.05 to $0.18 depending on the distributor, contract terms, and specific manufacturer pricing.

How do DEA production quotas affect the availability and price of this drug?

DEA production quotas limit the total amount of Schedule II controlled substances that can be manufactured annually in the U.S. For a high-volume generic like hydrocodone bitartrate and acetaminophen, current quotas are generally sufficient to meet demand, and thus have minimal direct impact on price or availability under normal market conditions. However, significant changes in quotas could influence supply.

What are the primary non-opioid alternatives influencing the market for this drug?

Key non-opioid alternatives include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen, topical analgesics (e.g., lidocaine patches, capsaicin creams), physical therapy, exercise, cognitive behavioral therapy, and newer non-opioid analgesic classes such as CGRP inhibitors for migraine.

Will the generic status of this drug prevent significant price increases?

Yes, the generic status ensures intense competition among multiple manufacturers. This competition, coupled with payer negotiations and formulary management by PBMs, will likely prevent significant price increases. Any cost pressures on manufacturers are more likely to result in reduced profit margins rather than substantial price hikes passed on to the market.

How might changes in state-level opioid prescribing laws impact the demand for NDC 00093-7355?

Stricter state-level prescribing laws, such as prescription drug monitoring program (PDMP) mandates, duration limits for opioid prescriptions, and requirements for alternative therapy discussions, will directly contribute to a reduction in the overall demand for hydrocodone bitartrate and acetaminophen products, including NDC 00093-7355.

Citations

[1] IQVIA. (n.d.). Prescription Data and Market Insights. (Accessed through proprietary market intelligence platforms, specific report not publicly cited).

[2] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act Schedules. Retrieved from https://www.dea.gov/drug-scheduling

[3] Healthcare distribution industry publications and pricing databases. (n.d.). Wholesaler Acquisition Cost and Net Pricing Trends. (Accessed through proprietary market intelligence platforms, specific report not publicly cited).